Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Business Wire
New data reinforce Mirum’s commitment to advancing therapies and improving the lives of patients across diverse rare liver diseases. FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that multiple presentations featuring data from its LIVMARLI (maralixibat) and volixibat clinical programs will be shared during the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting®, taking place November 7-11, 2025, in Washington, D.C.The presentations highlight Mirum’s continued progress in expanding the scientific and clinical foundation for new approaches to treating adult and pediatric rare liver diseases, including new findings from the VANTAGE trial and real-world studies.Oral PresentationA key highlight at this year’s meeting will be an oral presentation featuring additional analyses from the VANTAGE trial evaluating volixibat in adults with primary biliary cholangitis (PBC).Abstract
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X SyndromeBusiness Wire
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness Wire
MIRM
Earnings
- 11/4/25 - Beat
MIRM
Sec Filings
- 12/5/25 - Form SCHEDULE
- 12/2/25 - Form 4
- 12/1/25 - Form 144
- MIRM's page on the SEC website